Результаты поиска

Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.

ObjectivesThe current study aims to evaluate the safety and efficacy of anti-CD38 monoclonal antibodies (mAbs) among patients with relapsed/refractory multiple myeloma (RRMM) through meta-analysis.MethodsAs of June 2023, we searched PubMed, Web of Science, Embase and the Cochrane Library. Randomized controlled trials (RCTs) which compared the clinical outcomes of anti-CD38 mAbs plus immunomodulatory drugs (IMiDs) or proteasome inhibitors (PIs) plus dexamethasone and IMiDs (or PIs) and dexamethasone alone for RRMM patients were included. Efficacy outcomes were mainly evaluated with progression-

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.

BackgroundMultiple myeloma is currently the leading indication for autologous hematopoietic cell transplantation (AHCT). A prerequisite for AHCT is mobilization and collection of adequate blood graft to support high-dose therapy. Current mobilization strategies include granulocyte colony-stimulating factor (G-CSF) alone or in combination with chemotherapy most commonly cyclophosphamide (CY). More recently, plerixafor has become into agenda especially in patients who mobilize poorly. In the selection of a mobilization method, several factors should be considered.SummaryPreplanned collection tar

Совпадение в полном тексте источника
… Immunomodulatory Drugs Thalidomide has been used for the treatment of MM for two decades, initially as salvage treatment in heavily pretreated patients and later as induction therapy with dexamethasone or more recently in triplets like VTd [ 17 , 18 ]. … VRd triplet appears to be associated with a significant risk of collection failure (8.7%) with a G-CSF alone mobilization [ 19 ]. …

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.

Multiple myeloma (MM), the second most common hematologic malignancy, is characterized by the clonal expansion of plasma cells. Despite dramatic improvements in patients' survival over the past decade due to advances in therapy exploiting novel molecular targets (immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies), the treatment of relapsed and refractory disease remains challenging. Recent studies confirmed complex, dynamic, and heterogeneous genomic alterations without unifying gene mutations in MM patients. In the current review, we survey recent therapeutic strategies,

Характеристики и результаты вторичных гематологических магнатов после аутологической трансплантации стволовых клеток в случае множественной миеломы.

Автологическая трансплантация стволовых клеток (auto-SCT) по-прежнему является важной основой в многократной терапии миэломы (MM); вместе с тем существует повышенный риск развития второй первичной халатности, включая вторую гематологическую халатность (SHM). Мы провели ретроспективное исследование пациентов с MM, которые прошли авто-SCT в нашем учреждении между 1990 и 2022 и впоследствии разработан SHM. Среди 3401 пациентов с MM, которые прошли авто-SCT, 110 (В тыс.3.2%) разработан SHM [терапия, связанная с опухолью миэлоида (t-MN) = 98; острая лимфоболическая лейкемия в клетке B (t-B-ALL) = 1

The Precision Revolution in Hematologic Malignancies: A Decade of Transformative Immunotherapies and Targeted Agents.

This review describes the dramatic transformation that has occurred in the last ten years in the therapeutic landscape for hematologic malignancies, such as leukemias, lymphomas, myelomas, and myelodysplastic syndromes. Treatment paradigms have quickly changed from depending solely on cytotoxic chemotherapy to embracing precision medicine, driven by a previously unprecedented understanding of disease biology and precise molecular changes. The development of powerful immunotherapies (such as CAR T-cell therapy and bispecific antibodies) and innovative targeted agents (like BTK inhibitors, BCL-2

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the global, randomised, double-blind, placebo-controlled Phase III TOURMALINE-MM1 study of ixazomib-Rd (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma. IRd resulted in a significant improvement in progression-free survival versus placebo-Rd (median: 20·6 vs. 14·7 months; hazard

Совпадение в полном тексте источника
… The toxicity profile of the triplet is favourable and appears comparable to that of the Rd doublet; this represents a beneficial efficacy‐toxicity relationship given the PFS improvements seen. … Blood , 124 , 2467 – 2468 . 25301337 10.1182/blood-2014-06-583302 Rajkumar , S.V. ( 2012 ) Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? …

Applied information retrieval and multidisciplinary research: new mechanistic hypotheses in complex regional pain syndrome.

BackgroundCollaborative efforts of physicians and basic scientists are often necessary in the investigation of complex disorders. Difficulties can arise, however, when large amounts of information need to reviewed. Advanced information retrieval can be beneficial in combining and reviewing data obtained from the various scientific fields. In this paper, a team of investigators with varying backgrounds has applied advanced information retrieval methods, in the form of text mining and entity relationship tools, to review the current literature, with the intention to generate new insights into th

Бремя лечения, секвенирования и использования ресурсов здравоохранения в множестве миеломы в Латинской Америке: обзор целевой литературы.

Утверждение основных классов лекарственных препаратов позволило улучшить выживание пациентов с множественной миеломой (ММ). В то же время большинство пациентов сталкиваются с рецидивом или становятся противниками этих методов лечения, причем повторное лечение имеет ограниченную эффективность. Доступ к этим основным методам лечения в разных странах Латинской Америки (ЛАТАМ), что может привести к неоптимальным клиническим результатам. Цель этого целевого обзора литературы заключалась в том, чтобы понять эпидемиологию, бремя лечения, последовательность лечения и наличие MM в Аргентине, Бразилии,

Преимущество сокращения селинксорной дозы от исхода селинксора, борцезомиба и дексаметазона у пациентов с многократной миеломой lenalidomide-refractory: подгруппный анализ испытания БОСТОН.

Подгруппный анализ эффективности, безопасности и QOL у пациентов, получивших селинксор в сочетании с борцезомибами и дексаметазоном (SVd) с сокращением доз селинксора и без него, у которых в организме была болезнь линалидомида. фазы 3 Эксперимент БОСТОН продемонстрировал повышение эффективности, качества жизни (QOL) и уровня безопасности при сокращении селинксорной дозы в этой труднодоступной группе населения. Эти результаты свидетельствуют о том, что сокращение доз селинксора помогает оптимизировать лечение пациентов с многократным миэломой (ММ), получаемой SVd.

Contextualizing results of randomized trials in smoldering myeloma.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

< < Холистическое управление множественной миеломой > > : доклад по делу < < Терапия Сидды > > как дополнение к режиму Бортезомиба-Леналидомида-Дексаметасона (БЛД).

Множественная миелома (ММ) — сложная гематология, характеризующаяся клональным распространением плазменных клеток в костном мозге. Это вторая по распространенности гематологическая халатность, которая проявляется у пожилых пациентов. Инкорпорирование дополнительной медицины в обычные методы лечения рака все чаще наблюдается среди пациентов, что обусловлено такими факторами, как управление симптомами, целостное благосостояние и культурная увязка. В настоящем докладе представлена информация о комплексном управлении деятельностью 65-year-old Пациент мужского пола диагностировал ММ, который получа

Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma.

BACKGROUND Multiple myeloma (MM) is the second most common hematologic cancer with poor prognosis. Novel therapeutic strategies are needed to decrease the high mortality rate. The aim of this study was to identify prospective agents for MM. MATERIAL AND METHODS A microarray dataset was mined, which contains the transcriptome profiles of 588 MM patients. Univariate Cox analysis was performed to analyze the relationships between genes and clinical outcome. Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were determined. Protective and risky genes were uploaded to Connec

Совпадение в полном тексте источника
… These drugs are combined as doublets, triplets, and/or multiple drug regimens for MM treatments, and this makes the decisions about optimal therapy at diagnosis and relapse quite challenging [ 7 ]. Hence, novel therapeutic strategies are needed in order to decrease the mortality rate. …

Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma.

This study investigated the efficacy and safety of melphalan, cyclophosphamide, and dexamethasone (MCD) as a salvage regimen for heavily treated relapsed or refractory multiple myeloma patients. We retrospectively analyzed a total of 27 patients who received the MCD regimen between April 2011 and November 2013. The MCD regimen consisted of oral melphalan 6.75 mg/m2 on days 1-4, once-weekly dose of oral cyclophosphamide 300 mg/m2 and dexamethasone 20 mg/m2 on days 1-4 and days 15-18. Each cycle was repeated every 28 days. The median age of the patients was 66 years and the MCD regimen was initi

The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review.

Despite recent advancements in treatments, including proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies, multiple myeloma (MM) remains mostly incurable with patients frequently experiencing disease relapses due to therapy resistance. Hence there is an urgent need for innovative treatments for patients with relapsed and/or refractory MM (RRMM). This review examines Belantamab mafodotin, the first antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), which has shown efficacy in pre-clinical and clinical settings for RRMM. BCMA, a type III transmembra

Результаты, полученные пациентами фазы 3 Клинические испытания на рак крови: систематический обзор.

ВАЖНОСТЬ: Опубликованные результаты исследований свидетельствуют о том, что результаты, сообщенные пациентами (РО), не собираются и не сообщаются в ходе случайных клинических испытаний (РКТ) на твердые опухоли. Мало что известно об этой практике в РХТ для гематологических злокачественных новообразований. ЦЕЛЬ: Оценка распространенности ПРО как заранее определенных конечных точек в РСТ гематологических злокачественных новообразований и оценка отчетности по ПРО в соответствующих публикациях.ОБЗОР ДОКАЗАТЕЛЬСТВА: Все вопросы 8 :: в период с января были опубликованы журналы, известные как < &lt

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.

According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, bone marrow plasma cell infiltration >10% and <60%, and absence of any myeloma-defining event. Active multiple myeloma is preceded by SMM, with a median time to progression of approximately 5 years. Cases of SMM range from the extremes of "monoclonal gammopathy of undetermined significance-like", in which patients never progress during their lifetimes, to "early multiple myeloma", in which transformation into s

Совпадение в полном тексте источника
… Such approaches, briefly described below, generally comprise triplets including a proteasome inhibitor with an immunomodulatory drug + dexamethasone, monoclonal antibodies or even autologous stem cell transplantation. … The oral triplet ixazomib, lenalidomide + dexamethasone for nine cycles followed by 15 cycles of ixazomib + lenalidomide was investigated in patients with high-risk SMM in a phase II trial. 90 Based on preliminary results in the first 26 patients, grade 3 hypophosphatemia, leukopenia, and neutropenia …

Research progress in inducing immunogenic cell death of tumor cells.

Immunogenic cell death (ICD) is a regulated cell death (RCD) pathway. In response to physical and chemical signals, tumor cells activate specific signaling pathways that stimulate stress responses in the endoplasmic reticulum (ER) and expose damage-associated molecular patterns (DAMPs), which promote antitumor immune responses. As a result, the tumor microenvironment is altered, and many tumor cells are killed. The ICD response in tumor cells requires inducers. These inducers can be from different sources and contribute to the development of the ICD either indirectly or directly. The combinati

Therapeutic Advances in Oncology.

Around 77 new oncology drugs were approved by the FDA in the past five years; however, most cancers remain untreated. Small molecules and antibodies are dominant therapeutic modalities in oncology. Antibody-drug conjugates, bispecific antibodies, peptides, cell, and gene-therapies are emerging to address the unmet patient need. Advancement in the discovery and development platforms, identification of novel targets, and emergence of new technologies have greatly expanded the treatment options for patients. Here, we provide an overview of various therapeutic modalities and the current treatment

Снижение дозы по сравнению со стандартными кондиционирования мелфалами для автоматической трансплантации стволовых клеток в множестве миеломы: ретроспективное исследование с одним центром.

Это ретроспективное одноцентральное исследование позволило оценить эффективность и безопасность сокращенного режима кондиционирования мелфала (см.140–180 мг/м2 для аутологической трансплантации стволовых клеток (ASCT) у пациентов с множественной миеломой (MM), не имеющих права на стандартную дозу (ASCT)200 мг/м2. Клинические результаты сравнивались между пациентами, получившими сокращенную дозу, и стандартными дозированными мелфаланами по сравнению с а five- годовой период с предварительным анализом подгрупп в зависимости от возраста и почечной функции. Результаты показали, что, несмотря на ме

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.

PURPOSE: The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) with exclusively high-risk disease for whom prospective trials are limited, aiming to induce minimal residual disease (MRD) negativity. METHODS: This academic, investigator-initiated, multicenter, phase II trial enrolled patients with high-risk NDMM (HRNDMM) defined by mandatory International Staging System stage II/III combined with del17p, t(4;14), t(14;16), or more t